News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) Announces Publication of Key Data Showing Antitumor Activity of Prophage Vaccine (HSPPC-96) in Clinical Cancer Research



8/8/2012 9:19:38 AM

LEXINGTON, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology-based treatments for cancers and infectious diseases, today announced the publication of key clinical data from a Phase 1 trial of a Prophage Series vaccine (HSPPC-96; vitespen) to treat patients with recurrent glioblastoma multiforme (GBM).

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES